XUHC:F:F-Xtrackers (IE) Public Limited Company - Xtrackers MSCI USA Health Care UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 57.24

Change

-0.35 (-0.61)%

Market Cap

USD 0.85B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-10 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
PRAJ:F Amundi Index Solutions - Amund..

+0.15 (+0.53%)

USD 139.20B
SXR8:F iShares Core S&P 500 UCITS ETF..

+2.74 (+0.44%)

USD 111.88B
UIM5:F UBS (Lux) Fund Solutions - MSC..

+0.24 (+0.44%)

USD 106.38B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

-0.23 (-0.40%)

USD 105.77B
XDNY:F Xtrackers MSCI Japan ESG Scree..

+0.08 (+0.50%)

USD 62.83B
VUAA:F Vanguard S&P 500 UCITS Acc

+0.53 (+0.47%)

USD 51.63B
VUSA:F Vanguard Funds Public Limited ..

+0.60 (+0.54%)

USD 51.63B
SXRZ:F iShares VII PLC - iShares Nikk..

+2.60 (+1.06%)

USD 51.55B
XJSE:F Xtrackers II - Japan Governmen..

N/A

USD 43.00B
0ZC:F Zscaler Inc

+6.76 (+3.43%)

USD 37.92B

ETFs Containing XUHC:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 6.51% 71% C- 63% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.51% 71% C- 63% D
Trailing 12 Months  
Capital Gain 6.32% 38% F 50% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.32% 35% F 43% F
Trailing 5 Years  
Capital Gain 48.35% 73% C 70% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 48.35% 73% C 53% F
Average Annual (5 Year Horizon)  
Capital Gain 11.09% 71% C- 66% D+
Dividend Return 11.09% 69% C- 59% D-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 10.66% 65% D 90% A-
Risk Adjusted Return 104.01% 93% A 95% A
Market Capitalization 0.85B 73% C 55% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike